This is the first time that NSA-789, a new compound being developed for schizophrenia, will
be given to humans. Each healthy subject will receive a single dose, except for 8 subjects
who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.
- Healthy men and women between 18 and 50 years old.
- Women must be of non-child-bearing potential (not able to have children).
- Must be of normal body weight.